An antibiotic, sold since 1997, is the subject of three new lawsuits recently filed in East Texas and West Arkansas which argue the drug causes a higher incidence of tendon injuries.
Levaquin, a broad spectrum fluoroquinolone antibiotic is marketed as a first-line therapy for common bronchitis and sinusitis infections.
It is also approved for use in treatment of various upper respiratory infections, urinary tract infections, prostatitis and other bacterial infections. The lawsuits allege that the higher rate of injuries is notable in people over the age of 60 who are on corticosteroid therapy. |